Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.47 |
| ▸ | CPT2 | P23786 | 1/20 | 0.47 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.43 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 5/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.32 |
| ▸ | PPARG | P37231 | 7/20 | 0.32 |
| ▸ | PPARD | Q03181 | 7/20 | 0.32 |
| ▸ | PPARA | Q07869 | 7/20 | 0.32 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TLR2 | O60603 | 2/20 | 0.32 |
| ▸ | FABP4 | P15090 | 2/20 | 0.32 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.32 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6689414 | 0.98 | TBXAS1 (0.44) | TDP1FFAR1CPT2TBXAS1NAALAD2 | |
| SCHEMBL6508202 | 0.94 | FFAR1 (0.42) | TDP1FFAR1CPT2TBXAS1NAALAD2 | |
| SCHEMBL6510205 | 0.93 | TBXAS1 (0.42) | TDP1FFAR1CPT2TBXAS1NAALAD2 | |
| SCHEMBL6505954 | 0.92 | TBXAS1 (0.40) | TDP1FFAR1CPT2TBXAS1NAALAD2 | |
| SCHEMBL6694245 | 0.86 | FFAR1 (0.39) | TDP1FFAR1CPT2TBXAS1NAALAD2 | |
| SCHEMBL1831810 | 0.84 | TDP1 (0.62) | TDP1FFAR1CPT2TBXAS1NAALAD2 | |
| SCHEMBL4184422 | 0.84 | TDP1 (0.62) | TDP1FFAR1CPT2TBXAS1NAALAD2 | |
| SCHEMBL1833933 | 0.84 | TDP1 (0.62) | TDP1FFAR1CPT2TBXAS1NAALAD2 | |
| SCHEMBL6695504 | 0.84 | FFAR1 (0.70) | TDP1FFAR1CPT2TSHR | |
| SCHEMBL6697864 | 0.83 | NAALAD2 (0.37) | TDP1FFAR1CPT2TBXAS1NAALAD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2004531459-A | — | — | 2004-10-14 | — | — | JP | claimed |
| US-20040122091-A1 | Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. | 2004-06-24 | — | — | US | claimed |
| CN-1479721-A | Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol therapy and related applications | ͨ��ҽ�ƹ�˾ | 2004-03-03 | — | — | CN | claimed |
| US-6673780-B2 | SUCH AS 4-(4-(3-HYDROXY-3-METHYL-BUTANE-1-SULFINYLMETHYL)-PHENYLMETHANESULFINYL)-2 -METHYL-BUTAN1-OL FOR TREATING AND PREVENTING CARDIOVASCULAR DISEASES, DYSLIPIDEMIAS, DYSPROTEINEMIAS, AND GLUCOSE METABOLISM DISORDERS | ESPERION THERAPEUTICS, INC. | 2004-01-06 | — | — | US | claimed |
| EP-1366024-A2 | SULFOXIDE AND BIS-SULFOXIDE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | Esperion Therapeutics Inc. (US) | 2003-12-03 | — | — | EP | claimed |
| US-20030022865-A1 | Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. | 2003-01-30 | — | — | US | claimed |
| WO-2002030882-A2 | SULFOXIDE AND BIS-SULFOXIDE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2002-04-18 | — | — | WO | claimed |
| WO-2005047236-A1 | SULFOXIDE AND BIS-SULFOXIDE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2005-05-26 | — | — | WO | disclosed |
| CN-1479721-A | Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol therapy and related applications | ͨ��ҽ�ƹ�˾ | 2004-03-03 | — | — | CN | disclosed |
| US-6673780-B2 | SUCH AS 4-(4-(3-HYDROXY-3-METHYL-BUTANE-1-SULFINYLMETHYL)-PHENYLMETHANESULFINYL)-2 -METHYL-BUTAN1-OL FOR TREATING AND PREVENTING CARDIOVASCULAR DISEASES, DYSLIPIDEMIAS, DYSPROTEINEMIAS, AND GLUCOSE METABOLISM DISORDERS | ESPERION THERAPEUTICS, INC. | 2004-01-06 | — | — | US | disclosed |
| EP-1366024-A2 | SULFOXIDE AND BIS-SULFOXIDE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | Esperion Therapeutics Inc. (US) | 2003-12-03 | — | — | EP | disclosed |
| WO-2002030882-A9 | SULFOXIDE AND BIS-SULFOXIDE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS INC (US) | 2003-02-20 | — | — | WO | disclosed |
| WO-2002030882-A2 | SULFOXIDE AND BIS-SULFOXIDE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122091-A1 | Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses | NR1H2, NR1H3, APOB | TDP1 3062/4885FFAR1 186/4885CPT2 81/4885 |
| US-20030022865-A1 | Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses | NR1H2, NR1H3, APOB | TDP1 3062/4885FFAR1 186/4885CPT2 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.